SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, a privately-held therapeutic antibody platform and product company, has begun receipt of funds from grants totaling $860,482 awarded under the Qualifying Therapeutic Discovery Project program (QTDP). Funding has been awarded for four product programs, including the company’s differentiated anti-IL17 monoclonal antibody (mAb) program.
